Makishima F, Terada S, Mikami T, Suzuki E
Institute for Genetics, University of Cologne, Germany.
Cytotechnology. 1992;10(1):15-23. doi: 10.1007/BF00376096.
Monoclonal antibody production by hybridoma cells at moderately slowed growth states would be favorable for commercial scale production since cells can devote their resources to performing the differentiated function, immunoglobulin production. We found that a purified recombinant human interleukin-6, which had been reported to support or stimulate proliferation of B cell hybridoma/plasmacytoma cells, suppressed growth of a hybridoma cell line in serum-free medium. In the presence of the interleukin, the growth-suppressed cells were viable for remarkably long periods in batch culture, and after removal of the interleukin from the culture medium, they started to proliferate at their normal growth rate. As the concentration of the interleukin increased in the culture, the growth rate decreased and the specific antibody productivity (antibody production rate per cell) increased to 5-fold of control at 10 U ml-1 (2 ng ml-1) of the interleukin.
杂交瘤细胞在生长适度减缓状态下产生单克隆抗体有利于商业化规模生产，因为细胞能够将资源用于执行分化功能，即免疫球蛋白的产生。我们发现，一种纯化的重组人白细胞介素-6，据报道它能支持或刺激B细胞杂交瘤/浆细胞瘤细胞的增殖，但在无血清培养基中却抑制了一种杂交瘤细胞系的生长。在白细胞介素存在的情况下，生长受抑制的细胞在分批培养中能存活很长时间，并且从培养基中去除白细胞介素后，它们开始以正常生长速率增殖。随着培养基中白细胞介素浓度的增加，生长速率降低，而特异性抗体生产率（每细胞的抗体产生速率）在白细胞介素浓度为10 U/ml（2 ng/ml）时增加到对照的5倍。
